Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity

Maartje G. Huijbers; Anna Fleur D. Vink; Erik H. Niks; Ruben H. Westhuis; Erik W. van Zwet; Robert H. de Meel; Ricardo Rojas García; Jordi Díaz Manera; Jan B. Kuks; Rinse Klooster; Kirsten Straasheijm; Amelia Evoli; Isabel Illa; Silvère M. van der Maarel; Jan J. Verschuuren

doi:10.1016/j.jneuroim.2015.12.016

Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity

Maartje G. Huijbers^*, Anna Fleur D. Vink, Erik H. Niks, Ruben H. Westhuis, Erik W. van Zwet, Robert H. de Meel, Ricardo Rojas García, Jordi Díaz Manera, Jan B. Kuks, Rinse Klooster, Kirsten Straasheijm, Amelia Evoli, Isabel Illa, Silvère M. van der Maarel, Jan J. Verschuuren

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo › peer review

30 Citazioni (Scopus)

Abstract

Muscle weakness in MuSK myasthenia gravis (MG) is caused predominantly by IgG4 antibodies which block MuSK signalling and destabilize neuromuscular junctions. We determined whether the binding pattern of MuSK IgG4 antibodies change throughout the disease course ("epitope spreading"), and affect disease severity or treatment responsiveness.We mapped the MuSK epitopes of 255 longitudinal serum samples of 53 unique MuSK MG patients from three independent cohorts with ELISA.Antibodies against the MuSK Iglike-1 domain determine disease severity. Epitope spreading outside this domain did not contribute to disease severity nor to pyridostigmine responsiveness. This provides a rationale for epitope specific treatment strategies.

Lingua originale	Inglese
pagine (da-a)	82-88
Numero di pagine	7
Rivista	Journal of Neuroimmunology
Volume	291
Numero di pubblicazione	Febbraio
DOI	https://doi.org/10.1016/j.jneuroim.2015.12.016
Stato di pubblicazione	Pubblicato - 2016
Pubblicato esternamente	Sì

All Science Journal Classification (ASJC) codes

Immunologia e Allergia
Immunologia
Neurologia
Neurologia (clinica)

Keywords

80 and over
Adult
Aged
Autoantibodies
Cholinergic
Cholinesterase Inhibitors
Enzyme-Linked Immunosorbent Assay
Epitope Mapping
Epitope mapping
Female
Humans
IgG4
Immunology
Immunology and Allergy
Italy
Longitudinal Studies
Male
Middle Aged
MuSK
Myasthenia Gravis
Myasthenia gravis
Neurology
Neurology (clinical)
Neuromuscular junction
Receptor Protein-Tyrosine Kinases
Receptors
Severity of Illness Index
Spain
Statistics as Topic
Young Adult

Accesso al documento

10.1016/j.jneuroim.2015.12.016

Altri file e collegamenti

Cita questo

Huijbers, M. G., Vink, A. F. D., Niks, E. H., Westhuis, R. H., van Zwet, E. W., de Meel, R. H., Rojas García, R., Díaz Manera, J., Kuks, J. B., Klooster, R., Straasheijm, K., Evoli, A., Illa, I., van der Maarel, S. M., & Verschuuren, J. J. (2016). Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity. Journal of Neuroimmunology, 291(Febbraio), 82-88. https://doi.org/10.1016/j.jneuroim.2015.12.016

@article{44bdcba613c342f7a2f4c03ef46e9b1d,

title = "Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity",

abstract = "Muscle weakness in MuSK myasthenia gravis (MG) is caused predominantly by IgG4 antibodies which block MuSK signalling and destabilize neuromuscular junctions. We determined whether the binding pattern of MuSK IgG4 antibodies change throughout the disease course ({"}epitope spreading{"}), and affect disease severity or treatment responsiveness.We mapped the MuSK epitopes of 255 longitudinal serum samples of 53 unique MuSK MG patients from three independent cohorts with ELISA.Antibodies against the MuSK Iglike-1 domain determine disease severity. Epitope spreading outside this domain did not contribute to disease severity nor to pyridostigmine responsiveness. This provides a rationale for epitope specific treatment strategies.",

keywords = "80 and over, Adult, Aged, Autoantibodies, Cholinergic, Cholinesterase Inhibitors, Enzyme-Linked Immunosorbent Assay, Epitope Mapping, Epitope mapping, Female, Humans, IgG4, Immunology, Immunology and Allergy, Italy, Longitudinal Studies, Male, Middle Aged, MuSK, Myasthenia Gravis, Myasthenia gravis, Neurology, Neurology (clinical), Neuromuscular junction, Receptor Protein-Tyrosine Kinases, Receptors, Severity of Illness Index, Spain, Statistics as Topic, Young Adult, 80 and over, Adult, Aged, Autoantibodies, Cholinergic, Cholinesterase Inhibitors, Enzyme-Linked Immunosorbent Assay, Epitope Mapping, Epitope mapping, Female, Humans, IgG4, Immunology, Immunology and Allergy, Italy, Longitudinal Studies, Male, Middle Aged, MuSK, Myasthenia Gravis, Myasthenia gravis, Neurology, Neurology (clinical), Neuromuscular junction, Receptor Protein-Tyrosine Kinases, Receptors, Severity of Illness Index, Spain, Statistics as Topic, Young Adult",

author = "Huijbers, \{Maartje G.\} and Vink, \{Anna Fleur D.\} and Niks, \{Erik H.\} and Westhuis, \{Ruben H.\} and \{van Zwet\}, \{Erik W.\} and \{de Meel\}, \{Robert H.\} and \{Rojas Garc{\'i}a\}, Ricardo and \{D{\'i}az Manera\}, Jordi and Kuks, \{Jan B.\} and Rinse Klooster and Kirsten Straasheijm and Amelia Evoli and Isabel Illa and \{van der Maarel\}, \{Silv{\`e}re M.\} and Verschuuren, \{Jan J.\}",

year = "2016",

doi = "10.1016/j.jneuroim.2015.12.016",

language = "English",

volume = "291",

pages = "82--88",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier B.V.",

number = "Febbraio",

}

Huijbers, MG, Vink, AFD, Niks, EH, Westhuis, RH, van Zwet, EW, de Meel, RH, Rojas García, R, Díaz Manera, J, Kuks, JB, Klooster, R, Straasheijm, K, Evoli, A, Illa, I, van der Maarel, SM & Verschuuren, JJ 2016, 'Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity', Journal of Neuroimmunology, vol. 291, n. Febbraio, pagg. 82-88. https://doi.org/10.1016/j.jneuroim.2015.12.016

TY - JOUR

T1 - Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity

AU - Huijbers, Maartje G.

AU - Vink, Anna Fleur D.

AU - Niks, Erik H.

AU - Westhuis, Ruben H.

AU - van Zwet, Erik W.

AU - de Meel, Robert H.

AU - Rojas García, Ricardo

AU - Díaz Manera, Jordi

AU - Kuks, Jan B.

AU - Klooster, Rinse

AU - Straasheijm, Kirsten

AU - Evoli, Amelia

AU - Illa, Isabel

AU - van der Maarel, Silvère M.

AU - Verschuuren, Jan J.

PY - 2016

Y1 - 2016

N2 - Muscle weakness in MuSK myasthenia gravis (MG) is caused predominantly by IgG4 antibodies which block MuSK signalling and destabilize neuromuscular junctions. We determined whether the binding pattern of MuSK IgG4 antibodies change throughout the disease course ("epitope spreading"), and affect disease severity or treatment responsiveness.We mapped the MuSK epitopes of 255 longitudinal serum samples of 53 unique MuSK MG patients from three independent cohorts with ELISA.Antibodies against the MuSK Iglike-1 domain determine disease severity. Epitope spreading outside this domain did not contribute to disease severity nor to pyridostigmine responsiveness. This provides a rationale for epitope specific treatment strategies.

AB - Muscle weakness in MuSK myasthenia gravis (MG) is caused predominantly by IgG4 antibodies which block MuSK signalling and destabilize neuromuscular junctions. We determined whether the binding pattern of MuSK IgG4 antibodies change throughout the disease course ("epitope spreading"), and affect disease severity or treatment responsiveness.We mapped the MuSK epitopes of 255 longitudinal serum samples of 53 unique MuSK MG patients from three independent cohorts with ELISA.Antibodies against the MuSK Iglike-1 domain determine disease severity. Epitope spreading outside this domain did not contribute to disease severity nor to pyridostigmine responsiveness. This provides a rationale for epitope specific treatment strategies.

KW - 80 and over

KW - Adult

KW - Aged

KW - Autoantibodies

KW - Cholinergic

KW - Cholinesterase Inhibitors

KW - Enzyme-Linked Immunosorbent Assay

KW - Epitope Mapping

KW - Epitope mapping

KW - Female

KW - Humans

KW - IgG4

KW - Immunology

KW - Immunology and Allergy

KW - Italy

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - MuSK

KW - Myasthenia Gravis

KW - Myasthenia gravis

KW - Neurology

KW - Neurology (clinical)

KW - Neuromuscular junction

KW - Receptor Protein-Tyrosine Kinases

KW - Receptors

KW - Severity of Illness Index

KW - Spain

KW - Statistics as Topic

KW - Young Adult

KW - 80 and over

KW - Adult

KW - Aged

KW - Autoantibodies

KW - Cholinergic

KW - Cholinesterase Inhibitors

KW - Enzyme-Linked Immunosorbent Assay

KW - Epitope Mapping

KW - Epitope mapping

KW - Female

KW - Humans

KW - IgG4

KW - Immunology

KW - Immunology and Allergy

KW - Italy

KW - Longitudinal Studies

KW - Male

KW - Middle Aged

KW - MuSK

KW - Myasthenia Gravis

KW - Myasthenia gravis

KW - Neurology

KW - Neurology (clinical)

KW - Neuromuscular junction

KW - Receptor Protein-Tyrosine Kinases

KW - Receptors

KW - Severity of Illness Index

KW - Spain

KW - Statistics as Topic

KW - Young Adult

UR - https://publicatt.unicatt.it/handle/10807/94711

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84959378406&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84959378406&origin=inward

U2 - 10.1016/j.jneuroim.2015.12.016

DO - 10.1016/j.jneuroim.2015.12.016

M3 - Article

SN - 0165-5728

VL - 291

SP - 82

EP - 88

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

IS - Febbraio

ER -

Longitudinal epitope mapping in MuSK myasthenia gravis: Implications for disease severity

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo